BEIJING AOSAIKANG PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.45 CNY | -0.26% |
|
+2.42% | +5.82% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Capitalization 1 | 14,999 | 12,122 | 11,815 | 7,370 | 10,043 |
| Enterprise Value (EV) 1 | 13,712 | 10,673 | 10,142 | 5,815 | 8,406 |
| P/E ratio | 19.2 x | 16.7 x | 31 x | -33.1 x | -67.6 x |
| Yield | 1.36% | 1.53% | 0.79% | - | - |
| Capitalization / Revenue | 3.32 x | 3.2 x | 3.8 x | 3.94 x | 6.96 x |
| EV / Revenue | 3.03 x | 2.82 x | 3.26 x | 3.11 x | 5.82 x |
| EV / EBITDA | 14.7 x | 12.9 x | 25.3 x | -25.9 x | -47.6 x |
| EV / FCF | 140 x | 95.2 x | 38.4 x | -57.5 x | -137 x |
| FCF Yield | 0.72% | 1.05% | 2.6% | -1.74% | -0.73% |
| Price to Book | 5.97 x | 4 x | 3.67 x | 2.49 x | 3.52 x |
| Nbr of stocks (in thousands) | 928,160 | 928,160 | 928,160 | 928,160 | 928,160 |
| Reference price 2 | 16.16 | 13.06 | 12.73 | 7.940 | 10.82 |
| Announcement Date | 4/29/20 | 4/28/21 | 4/29/22 | 4/28/23 | 4/28/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 3,932 | 4,519 | 3,783 | 3,107 | 1,873 | 1,443 |
| EBITDA 1 | 797.3 | 930.5 | 825 | 401.2 | -224.1 | -176.5 |
| EBIT 1 | 715 | 842.7 | 732.6 | 309.7 | -313.2 | -258.2 |
| Operating Margin | 18.19% | 18.65% | 19.37% | 9.97% | -16.73% | -17.89% |
| Earnings before Tax (EBT) 1 | 754.9 | 887.9 | 821.2 | 406.1 | -262.5 | -200.9 |
| Net income 1 | 670.1 | 781 | 721.6 | 379.9 | -225.8 | -148.5 |
| Net margin | 17.04% | 17.28% | 19.08% | 12.23% | -12.06% | -10.29% |
| EPS 2 | 0.8900 | 0.8400 | 0.7800 | 0.4100 | -0.2400 | -0.1600 |
| Free Cash Flow 1 | 212.6 | 98.23 | 112.1 | 263.8 | -101.1 | -61.18 |
| FCF margin | 5.41% | 2.17% | 2.96% | 8.49% | -5.4% | -4.24% |
| FCF Conversion (EBITDA) | 26.66% | 10.56% | 13.59% | 65.75% | - | - |
| FCF Conversion (Net income) | 31.72% | 12.58% | 15.54% | 69.43% | - | - |
| Dividend per Share 2 | 0.1200 | 0.2200 | 0.2000 | 0.1000 | - | - |
| Announcement Date | 4/29/19 | 4/29/20 | 4/28/21 | 4/29/22 | 4/28/23 | 4/28/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1,111 | 1,287 | 1,449 | 1,674 | 1,554 | 1,637 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 213 | 98.2 | 112 | 264 | -101 | -61.2 |
| ROE (net income / shareholders' equity) | 43.4% | 35.8% | 26.1% | 12.2% | -8.53% | -6.89% |
| ROA (Net income/ Total Assets) | 16.6% | 15.8% | 12.2% | 5.14% | -5.48% | -4.65% |
| Assets 1 | 4,029 | 4,930 | 5,911 | 7,392 | 4,118 | 3,193 |
| Book Value Per Share 2 | 1.980 | 2.710 | 3.260 | 3.470 | 3.190 | 3.070 |
| Cash Flow per Share 2 | 1.170 | 1.280 | 1.480 | 1.260 | 0.8300 | 1.110 |
| Capex 1 | 95.8 | 169 | 200 | 134 | 150 | 129 |
| Capex / Sales | 2.44% | 3.74% | 5.28% | 4.31% | 8.03% | 8.96% |
| Announcement Date | 4/29/19 | 4/29/20 | 4/28/21 | 4/29/22 | 4/28/23 | 4/28/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +5.82% | 1.48B | |
| +32.95% | 700B | |
| +26.51% | 569B | |
| -4.97% | 358B | |
| +18.83% | 330B | |
| +3.54% | 287B | |
| +15.70% | 236B | |
| +6.68% | 202B | |
| -9.08% | 197B | |
| +6.70% | 161B |
- Stock Market
- Equities
- 002755 Stock
- Financials Beijing Aosaikang Pharmaceutical Co., Ltd.